Clinical trials: Abdominal Distention
Dyspepsia and Other Specified Disorders of Function of Stomach
Functional Dyspepsia Treatment Trial
Functional dyspepsia is a common gastrointestinal disorder. Symptoms can include stomach pain or discomfort, bloating, fullness after eating meals, and nausea.
- Trial name
- FDTT (NCT00248651)
- Testing
- Amitriptyline, Escitalopram
- Where
- 8 sites in United States, Canada
- Volunteers
- 292 people
- Sponsor
- Mayo Clinic
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.
- Trial name
- NCT02025725
- Testing
- Metoclopramide Nasal Spray
- Where
- 50 sites in United States
- Volunteers
- 205 people
- Sponsor
- Evoke Pharma
Asymptomatic Conditions
Assessing the Effect of Lettuce on Intestinal Water Content Through Magnetic Resonance Imaging of the Small Bowel
When patients have bowel surgery they are sometimes left with a stoma, where the small bowel exits onto the wall of the abdomen, not into the colon.
- Trial name
- LETIS (NCT02939716)
- Testing
- Rhubarb, Bread, Lettuce
- Where
- 2 sites in United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Nottingham
Chronic Constipation, Constipation
Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating
The purpose of this study is to evaluate the efficacy and safety of linaclotide compared with placebo in patients with chronic constipation (CC) and prominent abdominal bloating.
- Trial name
- NCT01642914
- Testing
- Linaclotide 290 micrograms, Linaclotide 145 micrograms
- Where
- 151 sites in United States, Canada
- Volunteers
- 487 people, healthy volunteers welcome
- Sponsor
- Forest Laboratories
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 2 (NCT00724126)
- Testing
- Rifaximin
- Where
- 88 sites in United States
- Volunteers
- 637 people
- Sponsor
- Bausch Health Americas, Inc.
Postoperative Ileus
Effect of TU-100 in Patients Undergoing Laparoscopic Colectomy
TU-100 is a gastrointestinal drug produced from the three botanical raw materials, Asian ginseng, Zanthoxylum fruit (Japanese pepper), and ginger, based on proprietary aqueous decoction and granulation technology.
- Trial name
- TU100P2T3 (NCT02232893)
- Testing
- Daikenchuto (TU-100)
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Tsumura USA
Abdominal Aortic Aneurysm
AARDVARK (Aortic Aneurysmal Regression of Dilation: Value of ACE-Inhibition on RisK)
Abdominal aortic aneurysms (AAA) are balloon-like swellings of the body's main blood vessel (aorta) as it courses through the abdomen. As a result of the National Aneurysm Screening programme many more of these will be detected.
- Trial name
- AARDVARK (NCT01118520)
- Testing
- perindopril arginine, amlodipine 5mgs
- Where
- 9 sites in United Kingdom
- Volunteers
- 224 people
- Sponsor
- Imperial College London
Functional Bowel Disorder
Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders
The parallel three-group study of efficacy and safety was planned to investigate the reduction in abdominal pain and bloating during treatment with the fixed-dose combination of Mebeverine + Simethicone versus Duspatalin® and…
- Trial name
- NCT05175131
- Testing
- Mebeverine+Simethicone, Mebeverine, Simethicone
- Where
- Russia
- Volunteers
- 465 people
- Sponsor
- Abbott
Gastroparesis
Placebo Controlled Trial of Botulinum Toxin for Gastroparesis
It is hypothesized that in some patients with gastroparesis increased pyloric tone may be a contributing feature. Botox relaxes the pylorus so that food can empty the stomach more rapidly.
- Trial name
- NCT00372970
- Testing
- Botulinum toxin A
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Temple University
Functional Dyspepsia
Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
The study is conducted in patients with functional dyspepsia or chronic gastritis. The purpose of this study is to: assess whether the dose of Itopride Hydrochloride 150 mg extended release tablets, taken once daily has a similar…
- Trial name
- NCT06217393
- Testing
- Itopride Hydrochloride 150 mg extended release tablets, Itopride Hydrochloride 50 mg film coated tablets
- Where
- 19 sites in Armenia, Malaysia and 3 more
- Volunteers
- 564 people
- Sponsor
- Abbott
Irritable Bowel Syndrome With Diarrhea
Mesalamine Granules for Irritable Bowel Syndrome (IBS) With Diarrhea
The purpose of this study is to determine the daily dose of mesalamine granules that will provide adequate relief from symptoms of IBS with diarrhea.
- Trial name
- NCT01177410
- Testing
- Mesalamine Granules 750 mg, Mesalamine Granules 1500 mg
- Where
- 20 sites in United States
- Volunteers
- 148 people
- Sponsor
- Bausch Health Americas, Inc.
Crohn Disease, Diabetic Gastroparesis
Rifaximin in Patients With Diabetic Gastroparesis
Researchers are trying to determine if subjects with diabetic gastroparesis and symptoms of bloating will have a greater improvement in bloating symptoms when treated with rifaximin.
- Trial name
- NCT04254549
- Testing
- Rifaximin
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Mayo Clinic
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis
The purpose of this study is evaluate the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult men.
- Trial name
- NCT02025751
- Testing
- Metoclopramide Nasal Spray
- Where
- 49 sites in United States
- Volunteers
- 53 people
- Sponsor
- Evoke Pharma
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.